AAAAAA

   
Results: 1-8 |
Results: 8
TOLERANCE AND ANTIVIRAL EFFECTS OF HIGH-DOSE INTERFERON-ALPHA B D IN PATIENTS WITH CHRONIC HEPATITIS-B/
Authors: RASCH MC SCHELLEKENS H VANDIJCK CMM HAAGSMA EB MICHIELSEN PP VANBUUREN AHJAM STOTTER H VANHATTUM J
Citation: Mc. Rasch et al., TOLERANCE AND ANTIVIRAL EFFECTS OF HIGH-DOSE INTERFERON-ALPHA B D IN PATIENTS WITH CHRONIC HEPATITIS-B/, Digestive diseases and sciences, 43(8), 1998, pp. 1719-1724
RELATION BETWEEN LABORATORY TEST-RESULTS AND HISTOLOGICAL HEPATITIS ACTIVITY IN INDIVIDUALS POSITIVE FOR HEPATITIS-B SURFACE-ANTIGEN AND ANTIBODIES TO HEPATITIS-B E-ANTIGEN
Authors: TERBORG F TENKATE FJW CUYPERS HTM LEENTVAARKUIJPERS A OOSTING J WERTHEIMVANDILLEN PME HONKOOP P RASCH MC DEMAN RA VANHATTUM J CHAMULEAU RAFM REESINK HW JONES EA
Citation: F. Terborg et al., RELATION BETWEEN LABORATORY TEST-RESULTS AND HISTOLOGICAL HEPATITIS ACTIVITY IN INDIVIDUALS POSITIVE FOR HEPATITIS-B SURFACE-ANTIGEN AND ANTIBODIES TO HEPATITIS-B E-ANTIGEN, Lancet, 351(9120), 1998, pp. 1914-1918
EFFECT OF LIVER IMPAIRMENT ON THE PHARMACOKINETICS OF TOLCAPONE AND ITS METABOLITES
Authors: JORGA KM KROODSMA JM FOTTELER B HEIZMANN P MEYER J RASCH MC VANHATTUM J
Citation: Km. Jorga et al., EFFECT OF LIVER IMPAIRMENT ON THE PHARMACOKINETICS OF TOLCAPONE AND ITS METABOLITES, Clinical pharmacology and therapeutics, 63(6), 1998, pp. 646-654
HEPATITIS-C TREATMENT IN DRUG-USERS (D-U) - FEASIBILITY USING A SPECIAL INFRASTRUCTURE
Authors: RASCH MC ALDERLIEFSTE G VANBERLO M BOERBOOM S JONGERHUIS M POL H WIND H VANHATTUM J
Citation: Mc. Rasch et al., HEPATITIS-C TREATMENT IN DRUG-USERS (D-U) - FEASIBILITY USING A SPECIAL INFRASTRUCTURE, Hepatology, 26(4), 1997, pp. 1351-1351
PREVALENCE OF GBV-C RNA AMONG SEVERAL POPULATIONS IN THE NETHERLANDS
Authors: JONGERIUS JM BOLAND GJ RASCH MC ITALIAANDER E VANDERREIJDEN JJ VANDERPOEL CL VANLEEUWEN EF VANHATTUM J
Citation: Jm. Jongerius et al., PREVALENCE OF GBV-C RNA AMONG SEVERAL POPULATIONS IN THE NETHERLANDS, Transfusion, 37(9), 1997, pp. 344-344
PREVALENCE OF GBV-C ANTI-E2 AMONG BLOOD-DONORS AND INTRAVENOUS-DRUG-USERS IN THE NETHERLANDS
Authors: JONGERIUS JM BOLAND GJ RASCH MC ITALIAANDER E VANDERREIJDEN JJ VANDERPOEL CL VONLEEUWEN EF VONHATTUM J
Citation: Jm. Jongerius et al., PREVALENCE OF GBV-C ANTI-E2 AMONG BLOOD-DONORS AND INTRAVENOUS-DRUG-USERS IN THE NETHERLANDS, Transfusion, 37(9), 1997, pp. 348-348
EFFICACY OF A NOVEL INTERFERON-ALPHA B D, GIVEN IN HIGH-DOSE - MONITORED BY QUANTITATIVE HBEAG, HBSAG AND HBV-DNA IN PATIENTS WITH CHRONIC HEPATITIS-B/
Authors: RASCH MC VANHATTUM J VANDIJCK CMM HAAGSMAN EB MICHIELSEN P SCHELLEKENS H
Citation: Mc. Rasch et al., EFFICACY OF A NOVEL INTERFERON-ALPHA B D, GIVEN IN HIGH-DOSE - MONITORED BY QUANTITATIVE HBEAG, HBSAG AND HBV-DNA IN PATIENTS WITH CHRONIC HEPATITIS-B/, Hepatology, 24(4), 1996, pp. 612-612
HIGH-DOSE INTERFERON-ALPHA B D IN PATIENTS WITH CHRONIC HEPATITIS-B/
Authors: RASCH MC VANHATTUM J SCHELLEKENS H VANDIJCK CMM HAAGSMA EB MICHIELSEN P VANBUUREN AHJAM STOTTER H
Citation: Mc. Rasch et al., HIGH-DOSE INTERFERON-ALPHA B D IN PATIENTS WITH CHRONIC HEPATITIS-B/, Gastroenterology, 110(4), 1996, pp. 1302-1302
Risultati: 1-8 |